Massimo Stefani

List of Publications by Year in Descending Order

139 papers	12,001 citations	52 h-index	108 g-index
143 ext. papers	12,896 ext. citations	5.7 avg, IF	6.47 L-index

#	Paper	IF	Citations
139	XENOHORMESIS UNDERLYES THE ANTI-AGING AND HEALTHY PROPERTIES OF OLIVE POLYPHENOLS.. *Mechanisms of Ageing and Development*, **2022**, 111620	5.6	2
138	Natural Compound from Olive Oil Inhibits S100A9 Amyloid Formation and Cytotoxicity: Implications for Preventing Alzheimer's Disease. *ACS Chemical Neuroscience*, **2021**, 12, 1905-1918	5.7	3
137	Olive Polyphenols: Antioxidant and Anti-Inflammatory Properties. *Antioxidants*, **2021**, 10,	7.1	26
136	The Amphipathic GM1 Molecule Stabilizes Amyloid Aggregates, Preventing their Cytotoxicity. *Biophysical Journal*, **2020**, 119, 326-336	2.9	2
135	Healthy Effects of Plant Polyphenols: Molecular Mechanisms. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	167
134	Healthspan Maintenance and Prevention of Parkinson's-like Phenotypes with Hydroxytyrosol and Oleuropein Aglycone in. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	67
133	Insight into the molecular mechanism underlying the inhibition of -synuclein aggregation by hydroxytyrosol. *Biochemical Pharmacology*, **2020**, 173, 113722	6	14
132	Allium roseum L. extract inhibits amyloid beta aggregation and toxicity involved in Alzheimer's disease. *PLoS ONE*, **2020**, 15, e0223815	3.7	4
131	Oleuropein aglycone and hydroxytyrosol interfere differently with toxic A -aggregation. *Food and Chemical Toxicology*, **2019**, 129, 1-12	4.7	36
130	1,2,4-trihydroxynaphthalene-2--D-glucopyranoside: A new powerful antioxidant and inhibitor of A -aggregation isolated from the leaves of. *Natural Product Research*, **2019**, 33, 1406-1414	2.3	7
129	1,2,4-trihydroxynaphthalene-2-O-D-glucopyranoside delays amyloid- -aggregation and reduces amyloid cytotoxicity. *BioFactors*, **2018**, 44, 272-280	6.1	1
128	A new purified Lawsoniaside remodels amyloid- -fibrillation into a less toxic and non-amyloidogenic pathway. *International Journal of Biological Macromolecules*, **2018**, 114, 830-835	7.9	1
127	Diet Supplementation with Hydroxytyrosol Ameliorates Brain Pathology and Restores Cognitive Functions in a Mouse Model of Amyloid- Deposition. *Journal of Alzheimer's Disease*, **2018**, 63, 1161-1172	4.3	26
126	Oleuropein aglycone: A polyphenol with different targets against amyloid toxicity. *Biochimica Et Biophysica Acta - General Subjects*, **2018**, 1862, 1432-1442	4	23
125	Toxic HypF-N Oligomers Selectively Bind the Plasma Membrane to Impair Cell Adhesion Capability. *Biophysical Journal*, **2018**, 114, 1357-1367	2.9	8
124	A FTIR microspectroscopy study of the structural and biochemical perturbations induced by natively folded and aggregated transthyretin in HL-1 cardiomyocytes. *Scientific Reports*, **2018**, 8, 12508	4.9	18
123	Screening for amyloid- -aggregation inhibitor and neuronal toxicity of eight Tunisian medicinal plants. *Industrial Crops and Products*, **2018**, 111, 823-833	5.9	7

122	Oleuropein aglycone stabilizes the monomeric -synuclein and favours the growth of non-toxic aggregates. *Scientific Reports*, **2018**, 8, 8337	4.9	39
121	Oleuropein Aglycone Protects against MAO-A-Induced Autophagy Impairment and Cardiomyocyte Death through Activation of TFEB. *Oxidative Medicine and Cellular Longevity*, **2018**, 2018, 8067592	6.7	28
120	Oleuropein aglycone and polyphenols from olive mill waste water ameliorate cognitive deficits and neuropathology. *British Journal of Clinical Pharmacology*, **2017**, 83, 54-62	3.8	54
119	A specific nanobody prevents amyloidogenesis of D76N -microglobulin in vitro and modifies its tissue distribution in vivo. *Scientific Reports*, **2017**, 7, 46711	4.9	12
118	Soluble Oligomers Require a Ganglioside to Trigger Neuronal Calcium Overload. *Journal of Alzheimer's Disease*, **2017**, 60, 923-938	4.3	27
117	Olive polyphenols: new promising agents to combat aging-associated neurodegeneration. *Expert Review of Neurotherapeutics*, **2017**, 17, 345-358	4.3	80
116	Biochemical and Electrophysiological Modification of Amyloid Transthyretin on Cardiomyocytes. *Biophysical Journal*, **2016**, 111, 2024-2038	2.9	11
115	Binding affinity of amyloid oligomers to cellular membranes is a generic indicator of cellular dysfunction in protein misfolding diseases. *Scientific Reports*, **2016**, 6, 32721	4.9	73
114	Single molecule experiments emphasize GM1 as a key player of the different cytotoxicity of structurally distinct A-42 oligomers. *Biochimica Et Biophysica Acta - Biomembranes*, **2016**, 1858, 386-92	3.8	20
113	Molecular insights into cell toxicity of a novel familial amyloidogenic variant of 2-microglobulin. *Journal of Cellular and Molecular Medicine*, **2016**, 20, 1443-56	5.6	20
112	The polyphenol Oleuropein aglycone hinders the growth of toxic transthyretin amyloid assemblies. *Journal of Nutritional Biochemistry*, **2016**, 30, 153-66	6.3	30
111	Interaction of toxic and non-toxic HypF-N oligomers with lipid bilayers investigated at high resolution with atomic force microscopy. *Oncotarget*, **2016**, 7, 44991-45004	3.3	20
110	Nutraceutical Properties of Olive Oil Polyphenols. An Itinerary from Cultured Cells through Animal Models to Humans. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	155
109	The Polyphenol Oleuropein Aglycone Modulates the PARP1-SIRT1 Interplay: An In Vitro and In Vivo Study. *Journal of Alzheimer's Disease*, **2016**, 54, 737-50	4.3	28
108	Oleuropein aglycone protects against pyroglutamylated-3 amyloid- toxicity: biochemical, epigenetic and functional correlates. *Neurobiology of Aging*, **2015**, 36, 648-63	5.6	76
107	Nutraceuticals and amyloid neurodegenerative diseases: a focus on natural phenols. *Expert Review of Neurotherapeutics*, **2015**, 15, 41-52	4.3	48
106	Oleuropein Aglycone: A Possible Drug against Degenerative Conditions. In Vivo Evidence of its Effectiveness against Alzheimer's Disease. *Journal of Alzheimer's Disease*, **2015**, 45, 679-88	4.3	55
105	Oleuropein aglycone induces autophagy via the AMPK/mTOR signalling pathway: a mechanistic insight. *Oncotarget*, **2015**, 6, 35344-57	3.3	85

104	Amyloid Aggregation: Role of Biological Membranes and the Aggregate-Membrane System. *Journal of Physical Chemistry Letters*, **2014**, 5, 517-27	6.4	72
103	Oleuropein aglycone counteracts A□2 toxicity in the rat brain. *Neuroscience Letters*, **2014**, 558, 67-72	3.3	56
102	Beneficial properties of natural phenols: highlight on protection against pathological conditions associated with amyloid aggregation. *BioFactors*, **2014**, 40, 482-93	6.1	72
101	Employing Alzheimer disease animal models for translational research: focus on dietary components. *Neurodegenerative Diseases*, **2014**, 13, 131-4	2.3	22
100	Mild exposure of RIN-5F □cells to human islet amyloid polypeptide aggregates upregulates antioxidant enzymes via NADPH oxidase-RAGE: an hormetic stimulus. *Redox Biology*, **2013**, 2, 114-22	11.3	11
99	Protein folding and aggregation into amyloid: the interference by natural phenolic compounds. *International Journal of Molecular Sciences*, **2013**, 14, 12411-57	6.3	132
98	Different ataxin-3 amyloid aggregates induce intracellular Ca(2+) deregulation by different mechanisms in cerebellar granule cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2013** , 1833, 3155-3165	4.9	19
97	The Oligomer Species: Mechanistics and Biochemistry **2013**, 127-150		
96	The amyloid-cell membrane system. The interplay between the biophysical features of oligomers/fibrils and cell membrane defines amyloid toxicity. *Biophysical Chemistry*, **2013**, 182, 30-43	3.5	80
95	Oleuropein aglycone protects transgenic C. elegans strains expressing A□2 by reducing plaque load and motor deficit. *PLoS ONE*, **2013**, 8, e58893	3.7	104
94	The polyphenol oleuropein aglycone protects TgCRND8 mice against A□plaque pathology. *PLoS ONE*, **2013**, 8, e71702	3.7	165
93	Structural features and cytotoxicity of amyloid oligomers: implications in Alzheimer□s disease and other diseases with amyloid deposits. *Progress in Neurobiology*, **2012**, 99, 226-45	10.9	138
92	Interactions of lysozyme with phospholipid vesicles: effects of vesicle biophysical features on protein misfolding and aggregation. *Soft Matter*, **2012**, 8, 9115	3.6	25
91	Lysozyme interaction with negatively charged lipid bilayers: protein aggregation and membrane fusion. *Soft Matter*, **2012**, 8, 4524	3.6	28
90	Membrane lipid composition and its physicochemical properties define cell vulnerability to aberrant protein oligomers. *Journal of Cell Science*, **2012**, 125, 2416-27	5.3	72
89	Toxic effects of amyloid fibrils on cell membranes: the importance of ganglioside GM1. *FASEB Journal*, **2012**, 26, 818-31	0.9	101
88	Amyloid Polymorphisms: Structural Basis and Significance in Biology and Molecular Medicine **2011**, 121-142		
87	Does azurin bind to the transactivation domain of p53? A Trp phosphorescence study. *Biophysical Chemistry*, **2011**, 159, 287-93	3.5	9

86	Neuronal differentiation of human mesenchymal stromal cells increases their resistance to Aβ42 aggregate toxicity. *Journal of Alzheimer's Disease*, **2011**, 27, 651-64	4.3	7
85	Aβ(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. *Current Alzheimer Research*, **2011**, 8, 841-52	3	100
84	Effect of tetracyclines on the dynamics of formation and destructuration of beta2-microglobulin amyloid fibrils. *Journal of Biological Chemistry*, **2011**, 286, 2121-31	5.4	77
83	Biochemical and biophysical features of both oligomer/fibril and cell membrane in amyloid cytotoxicity. *FEBS Journal*, **2010**, 277, 4602-13	5.7	144
82	A causative link between the structure of aberrant protein oligomers and their toxicity. *Nature Chemical Biology*, **2010**, 6, 140-7	11.7	443
81	Embryonic stem and haematopoietic progenitor cells resist to Aβ oligomer toxicity and maintain the differentiation potency in culture. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2010**, 17, 137-45	2.7	3
80	Structural polymorphism of amyloid oligomers and fibrils underlies different fibrillization pathways: immunogenicity and cytotoxicity. *Current Protein and Peptide Science*, **2010**, 11, 343-54	2.8	29
79	Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin. *Journal of Nutritional Biochemistry*, **2010**, 21, 726-35	6.3	95
78	Toxicity in Amyloid Diseases **2010**, 93-112		1
77	Protein aggregation diseases: toxicity of soluble prefibrillar aggregates and their clinical significance. *Methods in Molecular Biology*, **2010**, 648, 25-41	1.4	19
76	Cholesterol in Alzheimer's disease: unresolved questions. *Current Alzheimer Research*, **2009**, 6, 15-29	3	116
75	Proteomic analysis of cells exposed to prefibrillar aggregates of HypF-N. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2009**, 1794, 1243-50	4	3
74	A protective role for lipid raft cholesterol against amyloid-induced membrane damage in human neuroblastoma cells. *Biochimica Et Biophysica Acta - Biomembranes*, **2009**, 1788, 2204-16	3.8	54
73	Synthetic lipid vesicles recruit native-like aggregates and affect the aggregation process of the prion Ure2p: insights on vesicle permeabilization and charge selectivity. *Biophysical Journal*, **2009**, 96, 3319-30	2.9	15
72	beta2-Microglobulin is potentially neurotoxic, but the blood brain barrier is likely to protect the brain from its toxicity. *Nephrology Dialysis Transplantation*, **2009**, 24, 1176-81	4.3	24
71	Biological function in a non-native partially folded state of a protein. *EMBO Journal*, **2008**, 27, 1525-35	13	29
70	Protein folding and misfolding on surfaces. *International Journal of Molecular Sciences*, **2008**, 9, 2515-42	6.3	57
69	The (1-63) region of the p53 transactivation domain aggregates in vitro into cytotoxic amyloid assemblies. *Biophysical Journal*, **2008**, 94, 3635-46	2.9	40

68	Nonspecific interaction of prefibrillar amyloid aggregates with glutamatergic receptors results in Ca2+ increase in primary neuronal cells. *Journal of Biological Chemistry*, **2008**, 283, 29950-60	5.4	42
67	Differentiation increases the resistance of neuronal cells to amyloid toxicity. *Neurochemical Research*, **2008**, 33, 2516-31	4.6	24
66	Replicating neuroblastoma cells in different cell cycle phases display different vulnerability to amyloid toxicity. *Journal of Molecular Medicine*, **2008**, 86, 197-209	5.5	19
65	Generic cell dysfunction in neurodegenerative disorders: role of surfaces in early protein misfolding, aggregation, and aggregate cytotoxicity. *Neuroscientist*, **2007**, 13, 519-31	7.6	61
64	The yeast prion Ure2p native-like assemblies are toxic to mammalian cells regardless of their aggregation state. *Journal of Biological Chemistry*, **2006**, 281, 15337-44	5.4	39
63	The intrachain disulfide bridge is responsible of the unusual stability properties of novel acylphosphatase from Escherichia coli. *FEBS Letters*, **2006**, 580, 6763-8	3.8	8
62	Natively folded HypF-N and its early amyloid aggregates interact with phospholipid monolayers and destabilize supported phospholipid bilayers. *Biophysical Journal*, **2006**, 91, 4575-88	2.9	43
61	Assessing the role of aromatic residues in the amyloid aggregation of human muscle acylphosphatase. *Protein Science*, **2006**, 15, 862-70	6.3	93
60	Prefibrillar amyloid aggregates could be generic toxins in higher organisms. *Journal of Neuroscience*, **2006**, 26, 8160-7	6.6	199
59	Differing molecular mechanisms appear to underlie early toxicity of prefibrillar HypF-N aggregates to different cell types. *FEBS Journal*, **2006**, 273, 2206-22	5.7	13
58	Structure, conformational stability, and enzymatic properties of acylphosphatase from the hyperthermophile Sulfolobus solfataricus. *Proteins: Structure, Function and Bioinformatics*, **2006**, 62, 64-79	4.2	37
57	Reversal of protein aggregation provides evidence for multiple aggregated States. *Journal of Molecular Biology*, **2005**, 346, 603-16	6.5	82
56	Preliminary characterization of two different crystal forms of acylphosphatase from the hyperthermophile archaeon Sulfolobus solfataricus. *Acta Crystallographica Section F: Structural Biology Communications*, **2005**, 61, 144-6		3
55	Patterns of cell death triggered in two different cell lines by HypF-N prefibrillar aggregates. *FASEB Journal*, **2005**, 19, 437-9	0.9	36
54	Investigating the effects of mutations on protein aggregation in the cell. *Journal of Biological Chemistry*, **2005**, 280, 10607-13	5.4	64
53	Insights into the molecular basis of the differing susceptibility of varying cell types to the toxicity of amyloid aggregates. *Journal of Cell Science*, **2005**, 118, 3459-70	5.3	83
52	Aggregation of the Acylphosphatase from Sulfolobus solfataricus: the folded and partially unfolded states can both be precursors for amyloid formation. *Journal of Biological Chemistry*, **2004**, 279, 14111-9	5.4	89
51	Three-dimensional structural characterization of a novel Drosophila melanogaster acylphosphatase. *Acta Crystallographica Section D: Biological Crystallography*, **2004**, 60, 1177-9		16

50	Selection of antibody fragments specific for an alpha-helix region of acylphosphatase. *Journal of Molecular Recognition*, **2004**, 17, 62-6	2.6	2
49	Studying the folding process of the acylphosphatase from Sulfolobus solfataricus. A comparative analysis with other proteins from the same superfamily. *Biochemistry*, **2004**, 43, 9116-26	3.2	19
48	Prefibrillar amyloid protein aggregates share common features of cytotoxicity. *Journal of Biological Chemistry*, **2004**, 279, 31374-82	5.4	315
47	Protein misfolding and aggregation: new examples in medicine and biology of the dark side of the protein world. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2004**, 1739, 5-25	6.9	323
46	Monitoring the process of HypF fibrillization and liposome permeabilization by protofibrils. *Journal of Molecular Biology*, **2004**, 338, 943-57	6.5	96
45	Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution. *Journal of Molecular Medicine*, **2003**, 81, 678-99	5.5	1272
44	Rationalization of the effects of mutations on peptide and protein aggregation rates. *Nature*, **2003**, 424, 805-8	50.4	951
43	Relative influence of hydrophobicity and net charge in the aggregation of two homologous proteins. *Biochemistry*, **2003**, 42, 15078-83	3.2	105
42	Comparison of the folding processes of distantly related proteins. Importance of hydrophobic content in folding. *Journal of Molecular Biology*, **2003**, 330, 577-91	6.5	45
41	Crystallization and preliminary X-ray characterization of the acylphosphatase-like domain from the Escherichia coli hydrogenase maturation factor HypF. *Acta Crystallographica Section D: Biological Crystallography*, **2002**, 58, 524-5		5
40	Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. *Nature*, **2002**, 416, 507-11	50.4	2119
39	Kinetic partitioning of protein folding and aggregation. *Nature Structural Biology*, **2002**, 9, 137-43		343
38	Studies of the aggregation of mutant proteins in vitro provide insights into the genetics of amyloid diseases. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99 Suppl 4, 16419-26	11.5	246
37	Crystal structure and anion binding in the prokaryotic hydrogenase maturation factor HypF acylphosphatase-like domain. *Journal of Molecular Biology*, **2002**, 321, 785-96	6.5	62
36	Solution conditions can promote formation of either amyloid protofilaments or mature fibrils from the HypF N-terminal domain. *Protein Science*, **2001**, 10, 2541-7	6.3	38
35	Reduction of the amyloidogenicity of a protein by specific binding of ligands to the native conformation. *Protein Science*, **2001**, 10, 879-86	6.3	58
34	Folding and aggregation are selectively influenced by the conformational preferences of the alpha-helices of muscle acylphosphatase. *Journal of Biological Chemistry*, **2001**, 276, 37149-54	5.4	37
33	Detection of two partially structured species in the folding process of the amyloidogenic protein beta 2-microglobulin. *Journal of Molecular Biology*, **2001**, 307, 379-91	6.5	110

32	Initial denaturing conditions influence the slow folding phase of acylphosphatase associated with proline isomerization. *Protein Science*, **2000**, 9, 1466-73	6.3	4
31	Stabilisation of alpha-helices by site-directed mutagenesis reveals the importance of secondary structure in the transition state for acylphosphatase folding. *Journal of Molecular Biology*, **2000**, 300, 633-47	6.5	52
30	Mutational analysis of acylphosphatase suggests the importance of topology and contact order in protein folding. *Nature Structural Biology*, **1999**, 6, 1005-9		232
29	The low Mr phosphotyrosine protein phosphatase behaves differently when phosphorylated at Tyr131 or Tyr132 by Src kinase. *FEBS Letters*, **1999**, 456, 73-8	3.8	54
28	Thermodynamics and kinetics of folding of common-type acylphosphatase: comparison to the highly homologous muscle isoenzyme. *Biochemistry*, **1999**, 38, 2135-42	3.2	46
27	Sequence-specific recognition of peptide substrates by the low Mr phosphotyrosine protein phosphatase isoforms. *FEBS Letters*, **1998**, 422, 213-7	3.8	12
26	Conformational stability of muscle acylphosphatase: the role of temperature, denaturant concentration, and pH. *Biochemistry*, **1998**, 37, 1447-55	3.2	53
25	Structural characterization of the transition state for folding of muscle acylphosphatase. *Journal of Molecular Biology*, **1998**, 283, 893-903	6.5	49
24	Structural and kinetic investigations on the 15-21 and 42-45 loops of muscle acylphosphatase: evidence for their involvement in enzyme catalysis and conformational stabilization. *Biochemistry*, **1997**, 36, 7217-24	3.2	14
23	Structural, catalytic, and functional properties of low M(r), phosphotyrosine protein phosphatases. Evidence of a long evolutionary history. *International Journal of Biochemistry and Cell Biology*, **1997**, 29, 279-92	5.6	48
22	Structure and function of the low Mr phosphotyrosine protein phosphatases. *BBA - Proteins and Proteomics*, **1997**, 1341, 137-56		81
21	Looking for residues involved in the muscle acylphosphatase catalytic mechanism and structural stabilization: role of Asn41, Thr42, and Thr46. *Biochemistry*, **1996**, 35, 7077-83	3.2	46
20	C-terminal region contributes to muscle acylphosphatase three-dimensional structure stabilisation. *FEBS Letters*, **1996**, 384, 172-6	3.8	10
19	Expression, purification, and characterization of acylphosphatase muscular isoenzyme as fusion protein with glutathione S-transferase. *Protein Expression and Purification*, **1995**, 6, 799-805	2	24
18	Properties of N-terminus truncated and C-terminus mutated muscle acylphosphatases. *FEBS Letters* , **1995**, 362, 175-9	3.8	10
17	Arginine-23 is involved in the catalytic site of muscle acylphosphatase. *BBA - Proteins and Proteomics*, **1994**, 1208, 75-80		28
16	The crystal structure of a low-molecular-weight phosphotyrosine protein phosphatase. *Nature*, **1994**, 370, 575-8	50.4	216
15	Equilibrium unfolding studies of horse muscle acylphosphatase. *FEBS Journal*, **1994**, 225, 811-7		18

14	Aspartic-129 is an essential residue in the catalytic mechanism of the low M(r) phosphotyrosine protein phosphatase. *FEBS Letters*, **1994**, 350, 328-32	3.8	45
13	Crystallisation of a low molecular weight phosphotyrosine protein phosphatase from bovine liver. *FEBS Letters*, **1994**, 343, 107-8	3.8	3
12	Dephosphorylation of tyrosine phosphorylated synthetic peptides by rat liver phosphotyrosine protein phosphatase isoenzymes. *FEBS Letters*, **1993**, 326, 131-4	3.8	52
11	Expression and turnover of acylphosphatase (muscular isoenzyme) in L6 myoblasts during myogenesis. *Archives of Biochemistry and Biophysics*, **1992**, 294, 261-4	4.1	21
10	Preparation and properties of des-Tyr98 and des-Arg97-Tyr98 acylphosphatase (muscular isoenzyme). *International Journal of Peptide and Protein Research*, **1991**, 38, 278-84		2
9	The sequence-specific assignment of the 1H-NMR spectrum of an enzyme, horse-muscle acylphosphatase. *FEBS Journal*, **1989**, 182, 85-93		17
8	Mobility of secondary structure units of horse-muscle acylphosphatase. Relation to antigenicity. *FEBS Journal*, **1989**, 185, 99-103		9
7	Guinea pig acylphosphatase: the amino acid sequence. *The Protein Journal*, **1988**, 7, 417-26		10
6	Duck skeletal muscle acylphosphatase: Primary structure. *The Protein Journal*, **1986**, 5, 307-321		12
5	Rabbit skeletal muscle acylphosphatase: the amino acid sequence of form Ra1. *Archives of Biochemistry and Biophysics*, **1985**, 241, 418-24	4.1	27
4	The primary structure of turkey muscle acylphosphatase. *FEBS Journal*, **1983**, 137, 269-77		19
3	Hydrolysis by horse muscle acylphosphatase of (Ca2+ + Mg2+)-ATPase phosphorylated intermediate. *Archives of Biochemistry and Biophysics*, **1981**, 208, 37-41	4.1	34
2	Effect of acylphosphates on Ca2+ uptake by sarcoplasmic reticulum vesicles. *Archives of Biochemistry and Biophysics*, **1980**, 200, 357-63	4.1	12
1	Preparation and some properties of a dimeric form (S-S) of horse muscle acylphosphatase. *International Journal of Peptide and Protein Research*, **1979**, 14, 227-33		4